USA flag logo/image

An Official Website of the United States Government

Synergy of Inverse Scatter & Vibro-Acoustics

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
70613
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
CA105916
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
TECHNISCAN, INC.
3216 S Highland Drive Suite 200 SALT LAKE CITY, UT 84106
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Synergy of Inverse Scatter & Vibro-Acoustics
Agency: HHS
Contract: 1R43CA105916-01
Award Amount: $99,997.00
 

Abstract:

DESCRIPTION (provided by applicant): The objective of this Phase I SBIR grant application us to build a laboratory feasibility, breast cancer imaging system, that demonstrates synergistic benefits of combining Vibro-Acoustic Emission (VAE) technology with advanced Ultrasound Reflection Tomography (URT) and quantitative Ultrasound Inverse Scattering Tomography (UIST). A duplicate of a VAE imaging subsystem working at Mayo Clinic will be added to a working URT and UIST imaging subsystem at TSI. This new hybrid system will first be tested with cylindrical and 3-D anthropomorphic breast test objects (phantoms) that contain simulated benign and cancerous lesions and Micro Calcifications (MC) in patterns, which simulate benign and cancerous tissues, such a Ductile Carcinoma In Situ (DCIS) and Lobular Carcinoma (LC). As part of the Phase I feasibility study, a second level of testing will use at least 3 volunteers in a pilot study to determine the advantages of combining VAE with UIST and URT imaging modes. The sensitivity of VAE to MC will be combined with the high resolution, sensitivity and specificity of URT and UIST to soft tissue properties. These volunteers will be selected from a population with positive mammograms for MC that includes mammograms associated with probable benign, probable DCIS and probable LC. The small size of the pilot study reflects a compromise between using working sensitive equipment built for detecting MC in a controlled laboratory environment with testing this equipment as soon as possible on human subjects. Phase II work will add improved electronics; higher scan speed, more accurate imaging and a larger clinical study.

Principal Investigator:

Steven A. Johnson
8015210444
SJOHNSON@TECHNISCANMEDICAL.COM

Business Contact:

Barry Hanover
8015210444
BHANOVER@TECHNISCANMEDICAL.COM
Small Business Information at Submission:

TECHNISCAN, INC.
1011 EAST MURRAY HOLLADAY ROAD SUITE 100 SALT LAKE CITY, UT 84117

EIN/Tax ID: 870427600
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No